
A SCOTTISH medical technology company has announced £2.1 million additional seed financing – in an oversubscribed funding round – to complete its first human trials.
Based on research from Edinburgh University professors Tim Aitman and Mark Bradley, Biocaptiva have developed BioCaptis, a device slated to “transform liquid biopsy testing”, which is a type of blood test commonly used in the diagnosis and management of cancer.